Education
About Us
Working with TipRanks
Follow Us
Eton Pharmaceuticals Inc (ETON)
NASDAQ:ETON
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.03Last Year’s EPS
-0.03Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 18, 2025
|% Change Since: -11.64%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
Eton Pharmaceuticals reported strong revenue growth and strategic acquisitions, with a clear path to increasing its market presence. However, challenges remain in managing SG&A expenses and overcoming historical access issues for some products.Company Guidance
During the Eton Pharmaceuticals, Inc. conference call, the company provided robust guidance for 2025, highlighting several key metrics and strategic initiatives. Eton anticipates achieving an annual revenue run rate of approximately $80 million by the end of 2025, driven by the integration of recent acquisitions such as Increlex and Galzum, and the launch of ET400. The company expects a significant improvement in adjusted gross margins, targeting around 70% for 2025, due to the introduction of higher-margin products. SG&A expenses are projected to grow by 30-40% in 2025 to support the new product launches but will increase at a much slower rate than revenue. Eton has maintained a track record of 16 consecutive quarters of revenue growth and aims to reach $100 million in revenue in the near term with a long-term goal of achieving much higher levels as its pipeline progresses.Record-Breaking Revenue Growth
Eton Pharmaceuticals reported its 16th consecutive quarter of sequential product sales growth with Q4 2024 revenue at $11.6 million, marking a 59% year-over-year increase.
Successful Acquisitions
The acquisitions of Acrolex and Galzum are expected to significantly impact 2025 revenue, with immediate integration into the company's growth strategy.
Strong Financial Outlook
Eton Pharmaceuticals expects to reach $100 million in annual revenue in the near term and projects an 80 million dollar annual revenue run rate by the end of 2025.
Pipeline and Product Expansion
The company is preparing for significant launches, including ET400 and other pipeline products, with ET600 passing a pivotal clinical study.
---
ETON Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ETON Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 18, 2025 | $15.29 | $14.68 | -3.99% |
| Nov 12, 2024 | $9.17 | $10.60 | +15.59% |
| Aug 08, 2024 | $3.62 | $3.72 | +2.76% |
| May 09, 2024 | $3.44 | $3.43 | -0.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Eton Pharmaceuticals Inc (ETON) report earnings?
Eton Pharmaceuticals Inc (ETON) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Eton Pharmaceuticals Inc (ETON) earnings time?
Eton Pharmaceuticals Inc (ETON) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ETON EPS forecast?
ETON EPS forecast for the fiscal quarter 2025 (Q1) is 0.03.
---
